Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma

S. Ferrari, A. Brach Del Prever, E. Palmerini, E. Staals, M. Berta, A. Balladelli, P. Picci, F. Fagioli, G. Bacci, D. Vanel

Research output: Contribution to journalArticle

Abstract

Aim. To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods. Thirty-seven EFT patients [median age 17 years (645 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results. Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty-five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression. Conclusions. In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option.

Original languageEnglish
Pages (from-to)581-584
Number of pages4
JournalPediatric Blood and Cancer
Volume52
Issue number5
DOIs
Publication statusPublished - May 2009

Fingerprint

Ifosfamide
Ewing's Sarcoma
Drug Therapy
Neoplasms
Neutropenia

Keywords

  • Ewing sarcoma family tumors
  • High-dose ifosfamide
  • Radiographic response
  • Toxicity

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Ferrari, S., Del Prever, A. B., Palmerini, E., Staals, E., Berta, M., Balladelli, A., ... Vanel, D. (2009). Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma. Pediatric Blood and Cancer, 52(5), 581-584. https://doi.org/10.1002/pbc.21917

Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma. / Ferrari, S.; Del Prever, A. Brach; Palmerini, E.; Staals, E.; Berta, M.; Balladelli, A.; Picci, P.; Fagioli, F.; Bacci, G.; Vanel, D.

In: Pediatric Blood and Cancer, Vol. 52, No. 5, 05.2009, p. 581-584.

Research output: Contribution to journalArticle

Ferrari, S, Del Prever, AB, Palmerini, E, Staals, E, Berta, M, Balladelli, A, Picci, P, Fagioli, F, Bacci, G & Vanel, D 2009, 'Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma', Pediatric Blood and Cancer, vol. 52, no. 5, pp. 581-584. https://doi.org/10.1002/pbc.21917
Ferrari, S. ; Del Prever, A. Brach ; Palmerini, E. ; Staals, E. ; Berta, M. ; Balladelli, A. ; Picci, P. ; Fagioli, F. ; Bacci, G. ; Vanel, D. / Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma. In: Pediatric Blood and Cancer. 2009 ; Vol. 52, No. 5. pp. 581-584.
@article{d2b337e270da48e1bd26edf0a71a614f,
title = "Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma",
abstract = "Aim. To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods. Thirty-seven EFT patients [median age 17 years (645 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results. Transient Grade 4 neutropenia and thrombocytopenia in 97{\%} and 54{\%} HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty-five patients were evaluable: 12 (34{\%}) had complete (2) or partial (10) response, 11 (32{\%}) had stable disease, and 12 (34{\%}) had progression. Conclusions. In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option.",
keywords = "Ewing sarcoma family tumors, High-dose ifosfamide, Radiographic response, Toxicity",
author = "S. Ferrari and {Del Prever}, {A. Brach} and E. Palmerini and E. Staals and M. Berta and A. Balladelli and P. Picci and F. Fagioli and G. Bacci and D. Vanel",
year = "2009",
month = "5",
doi = "10.1002/pbc.21917",
language = "English",
volume = "52",
pages = "581--584",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma

AU - Ferrari, S.

AU - Del Prever, A. Brach

AU - Palmerini, E.

AU - Staals, E.

AU - Berta, M.

AU - Balladelli, A.

AU - Picci, P.

AU - Fagioli, F.

AU - Bacci, G.

AU - Vanel, D.

PY - 2009/5

Y1 - 2009/5

N2 - Aim. To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods. Thirty-seven EFT patients [median age 17 years (645 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results. Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty-five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression. Conclusions. In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option.

AB - Aim. To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods. Thirty-seven EFT patients [median age 17 years (645 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results. Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty-five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression. Conclusions. In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option.

KW - Ewing sarcoma family tumors

KW - High-dose ifosfamide

KW - Radiographic response

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=63649140230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63649140230&partnerID=8YFLogxK

U2 - 10.1002/pbc.21917

DO - 10.1002/pbc.21917

M3 - Article

C2 - 19142994

AN - SCOPUS:63649140230

VL - 52

SP - 581

EP - 584

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -